Mad Money w/ Jim Cramer Mad Money w/ Jim Cramer 1/14/25
Jan 15, 2025
Robert Ford, Chairman and CEO of Abbott Labs, shares insights on the company’s innovative glucose monitoring technology and diversification strategies. Rob Davis of Merck discusses their promising oncology pipeline and the significance of Gardasil amidst challenges. Len Schleifer from Regeneron Pharmaceuticals highlights their focus on groundbreaking drug development and long-term vision in healthcare. Together, they explore the evolving landscape of the pharmaceutical industry and the impact of innovation on market dynamics.
AI Snips
Chapters
Transcript
Episode notes
Buy Lilly on Weakness
- Consider buying Eli Lilly stock on weakness, despite short-term concerns.
- The company's wonder drug, Mounjaro, has many potential applications.
Merck's Undervalued Acquisition
- Merck, known for Keytruda, acquired Acceleron and its promising drug Wynrevere.
- Wynrevere treats pulmonary arterial hypertension, a typically fatal disease.
Regeneron's Potential
- Regeneron's stock has dropped significantly due to competition for its drug EYLEA.
- Despite this, the company is working on 40 different compounds.